Role of leukotriene B4 in 5-lipoxygenase metabolite- and allergy-induced itch-associated responses in mice. 2010

Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
Research and Development Center, Santen Pharmaceutical Co., Ltd., Ikoma, Nara 630-0101, Japan. ftsuji@minuet.plala.or.jp

We investigated the role of leukotriene (LT) B(4) in 5-lipoxygenase metabolite- and allergy-induced itch-associated responses using SA6541, an LTA(4) hydrolase inhibitor. Itch-associated responses were induced by intradermal injection of 5-hydroperoxyeicosatetraenoic acid (HPETE), a precursor of 5-lipoxygenase metabolites, and passive cutaneous anaphylaxis in ICR mice. By screening molecules related to arachidonic acid metabolism or pruritus, SA6541 was found to be a specific inhibitor of LTA(4) hydrolase. Pharmacokinetic studies confirmed the specificity of SA6541 at an oral dose of 100 mg/kg in mice. 5-HPETE induced scratching behavior, which was inhibited by SA6541 (100 mg/kg). However, SA6541 (100 mg/kg) hardly attenuated the 5-HPETE-induced increase in vascular permeability. Moreover, SA6541 (100 mg/kg) partially attenuated scratching behavior, but did not affect the increase in vascular permeability caused by passive cutaneous anaphylaxis. On the other hand, ketotifen fumarate, a histamine H1 antagonist, strongly inhibited the scratching behavior and the increase in vascular permeability caused by passive cutaneous anaphylaxis. These results suggest that LTB(4) is an endogenous itch mediator in the skin and is involved in the pruritus response in allergic reactions.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007665 Ketotifen A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. 4,9-Dihydro-4-(1-methyl-4-piperidylidene)-10H-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one,Ketotifen Fumarate,Ketotifene,Ketotiphen,Ketotiphene,Zaditen,Fumarate, Ketotifen
D007975 Leukotriene B4 The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) 5,12-HETE,5,12-diHETE,LTB4,Leukotriene B,Leukotriene B-4,Leukotrienes B,5,12 HETE,5,12 diHETE,B-4, Leukotriene,Leukotriene B 4
D008084 Lipoxygenase An enzyme of the oxidoreductase class primarily found in PLANTS. It catalyzes reactions between linoleate and other fatty acids and oxygen to form hydroperoxy-fatty acid derivatives. Lipoxidase,Linoleate-Oxygen Oxidoreductase,Lipoxygenase-1,Lipoxygenase-2,Linoleate Oxygen Oxidoreductase,Lipoxygenase 1,Lipoxygenase 2,Oxidoreductase, Linoleate-Oxygen
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010323 Passive Cutaneous Anaphylaxis An evanescent cutaneous reaction occurring when antibody is injected into a local area on the skin and antigen is subsequently injected intravenously along with a dye. The dye makes the rapidly occurring capillary dilatation and increased vascular permeability readily visible by leakage into the reaction site. PCA is a sensitive reaction for detecting very small quantities of antibodies and is also a method for studying the mechanisms of immediate hypersensitivity. Anaphylaxis, Passive Cutaneous,PCA,Cutaneous Anaphylaxis, Passive
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011537 Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. Itching,Pruritis
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities

Related Publications

Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
September 2007, Journal of pharmacological sciences,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
July 1998, European journal of pharmacology,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
June 1996, FEBS letters,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
April 1997, The American journal of physiology,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
August 2014, Pharmacological reports : PR,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
October 2006, European journal of pharmacology,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
December 1999, Journal of immunology (Baltimore, Md. : 1950),
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
September 1994, Journal of lipid mediators and cell signalling,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
September 1992, British journal of pharmacology,
Fumio Tsuji, and Hiroyuki Aono, and Takashi Tsuboi, and Tadahiro Murakami, and Hiroshi Enomoto, and Keiko Mizutani, and Naoki Inagaki
February 1992, Veterinary immunology and immunopathology,
Copied contents to your clipboard!